Emergent BioSolutions Inc. (EBS)
NYSE: EBS · Real-Time Price · USD
4.590
+0.100 (2.23%)
At close: Aug 14, 2026, 4:00 PM EDT
4.570
-0.020 (-0.44%)
After-hours: Aug 14, 2026, 7:34 PM EDT

Emergent BioSolutions Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-176.852.6-190.6-760.5-211.6219.5
Depreciation & Amortization
94.495.8108.8125.1130.6123.8
Other Amortization
8.59.87.421.34.14.1
Loss (Gain) From Sale of Assets
3.74.5-3.5-53.13.6-
Asset Writedown & Restructuring Costs
203.512.227.2524.919.441.7
Stock-Based Compensation
18.916.21823.145.142.4
Other Operating Activities
21.41.92.7-16.8-23.233.7
Change in Accounts Receivable
-127.425.5-24.4-21.6118.1-16.2
Change in Inventory
36.4-30.3-24.50.6-57.1-66.6
Change in Accounts Payable
3-8.4-3310.6-14-1.6
Change in Unearned Revenue
11.85.2-20.35.99.6-31.8
Change in Income Taxes
4.2-1.723.3-16.228.7-31.3
Change in Other Net Operating Assets
-3.9-12.7167.6-49.6-87.42.5
Operating Cash Flow
97.7170.658.7-206.3-34.1320.2
Operating Cash Flow Growth
-42.19%190.63%----40.36%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-11.8-13.8-22.9-51.6-115.8-224.1
Sale of Property, Plant & Equipment
0.238.27.9---
Divestitures
--110.2270.2--
Sale (Purchase) of Intangibles
-50.45030-6.3-243.7-
Other Investing Activities
--5---21.8-
Investing Cash Flow
-6269.4125.2212.3-381.3-224.1

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
--28420598-
Long-Term Debt Repaid
--112.5-482.4-563.4-33.8-35.9
Total Debt Repaid
-262.5-112.5-482.4-563.4-33.8-35.9
Net Debt Issued (Repaid)
-117-112.5-198.4-543.4564.2-35.9
Issuance of Common Stock
2.82.210.810.2515.9
Repurchase of Common Stock
-39.9-26.3-1.2-2.5-88-119.8
Other Financing Activities
-11.5--1.2---1.2
Financing Cash Flow
-165.6-136.6-190-535.7481.2-141

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-0.20.1--1.20.5-0.3
Net Cash Flow
-130.1103.5-6.1-530.966.3-45.2

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
85.9156.835.8-257.9-149.996.1
Free Cash Flow Growth
-44.58%337.99%----75.67%
Free Cash Flow Margin
11.15%21.11%3.43%-24.58%-13.41%5.42%
Free Cash Flow Per Share
1.652.770.68-5.04-2.991.78
Levered Free Cash Flow
37.5205.3958.5-88.6-203.1339.19
Unlevered Free Cash Flow
60.81232.6595.48-54.96-183.9156.65

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Interest Paid
41.549.76468.33330.4
Cash Income Tax Paid
334026.552.86.271.6
Change in Working Capital
-75.9-22.488.7-70.3-2.1-145
SEC Filings: 10-K · 10-Q